FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...
A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...
The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US. The FDA has approved Eydenzelt (aflibercept-boav), an aflibercept ...
The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market entries enhancing patient care. The global biosimilar industry experienced ...
A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants. Stivant, demonstrated similar efficacy and safety to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback